文献速递眼底病与葡萄膜炎

2毫克玻璃体内注射ziv-aflibercept的短期安全性

SHORT-TERM SAFETY OF 2 MG INTRAVITREAL ZIV-AFLIBERCEPT.
PubMed 文献 · Retina · 2017-01-01

本研究评估单次玻璃体内注射2毫克ziv-aflibercept(0.08毫升)治疗脉络膜新生血管膜的安全性。21只眼在注射后1个月内未出现临床毒性或视网膜电图异常,最佳矫正视力无显著变化,黄斑中心亚区厚度显著改善。

要点

  • 单次玻璃体内注射2毫克ziv-aflibercept(0.08毫升)在1个月内未观察到临床毒性或眼内炎症。
  • 视网膜电图b/a比值从基线至1个月无显著变化(暗适应P=0.89;明适应P=0.13)。
  • 黄斑中心亚区厚度从343±177微米显著降至210±133微米(P=0.01)。

核心结论

  • 单次玻璃体内注射2毫克ziv-aflibercept(0.08毫升)在1个月内似乎安全。

研究设计与样本

  • 研究纳入因多种病因导致脉络膜新生血管膜的眼,每只眼接受单次玻璃体内注射2毫克ziv-aflibercept(0.08毫升)。
  • 在基线及注射后第1天、第7天、第30天进行全面的眼科检查和详细的全身评估,并在基线和第30天进行标准视网膜电图检查。

主要发现

  • 共20例患者(12例男性)的21只眼接受注射,病因包括年龄相关性黄斑变性(14只眼)、息肉状脉络膜血管病变(3只眼)、近视(2只眼)和特发性中心凹旁毛细血管扩张(2只眼)。
  • 注射后无患者主诉视力恶化或疼痛,未见眼内炎症。
  • 视网膜电图b/a比值从基线至1个月无显著变化(暗适应P=0.89;明适应P=0.13),平均眼压无变化(14.2±3.6 mmHg vs 13.7±3.0 mmHg;P=0.62)。
  • 平均最佳矫正视力从基线至1个月无显著变化(0.66±0.37 logMAR [Snellen等效20/100] vs 0.61±0.35 logMAR [Snellen等效20/80];P=0.72),但黄斑中心亚区厚度显著改善(343±177 μm vs 210±133 μm;P=0.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety of single intravitreal 2 mg ziv-aflibercept (0.08 mL) injections for the treatment of choroidal neovascular membranes (CNVM). METHODS: Eyes with choroidal neovascular membranes because of several conditions each received single intravitreal injections of 2 mg ziv-aflibercept (0.08 mL). Comprehensive ophthalmic examinations and detailed systemic evaluations were performed at baseline and Days 1, 7, and 30 after injections. Standard electroretinography was performed at baseline and Day 30. Primary outcome measures consisted of safety assessments (signs of clinical toxicity and electroretinographic abnormalities). Secondary outcome measures included changes in best-corrected visual acuity (BCVA) and central subfield thickness (CST) of the macula. RESULTS: Twenty-one eyes of 20 patients (12 males) received injections. Etiologies responsible for the choroidal neovascular membranes included age-related macular degeneration (14), polypoidal choroidal vasculopathy (PCV) (3), myopia (2), and idiopathic juxtafoveal telangiectasia (2). None of the patients complained of worsening vision or pain after the intravitreal injections and no intraocular inflammation was seen. No significant changes in the electroretinographic b/a ratio from baseline to 1 month were measured (scotopic: P = 0.89; photopic: P = 0.13) and mean intraocular pressures were unchanged (14.2 ± 3.6 vs. 13.7 ± 3.0 mmHg; P = 0.62). Mean best-corrected visual acuity did not change significantly from baseline to 1 month (0.66 ± 0.37 logMAR [Snellen equivalent: 20/100] vs. 0.61 ± 0.35 logMAR [Snellen equivalent: 20/80]; P = 0.72) but significant improvements in central subfield thickness were seen (343 ± 177 vs. 210 ± 133 μm; P = 0.01). CONCLUSION: Single intravitreal injections of 2 mg ziv-aflibercept (0.08 mL) appear to be safe through 1 month.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Chhablani J, Dedhia CJ, Peguda HK, et al. SHORT-TERM SAFETY OF 2 MG INTRAVITREAL ZIV-AFLIBERCEPT. Retina. 2017. PMID: 28060148. doi:10.1097/IAE.0000000000001440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。